Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 3/1997

01-09-1997

Early evaluation of liposomal daunorubicin (DaunoXome®, Nexstar) in the treatment of relapsed and refractory lymphoma

Authors: Deborah S. Richardson, Stephen M. Kelsey, Stephen A. Johnson, Mary Tighe, James D. Cavenagh, Adrian C. Newland

Published in: Investigational New Drugs | Issue 3/1997

Login to get access
Metadata
Title
Early evaluation of liposomal daunorubicin (DaunoXome®, Nexstar) in the treatment of relapsed and refractory lymphoma
Authors
Deborah S. Richardson
Stephen M. Kelsey
Stephen A. Johnson
Mary Tighe
James D. Cavenagh
Adrian C. Newland
Publication date
01-09-1997
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 3/1997
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1023/A:1005879219554

Other articles of this Issue 3/1997

Investigational New Drugs 3/1997 Go to the issue

OriginalPaper

Phase II trial to topotecan in hepatocellular carcinoma: A Southwest Oncology Group study

OriginalPaper

A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors

OriginalPaper

Preclinical pharmacokinetic, antitumor and toxicity studies with CL-994 (N-acetyldinaline)

OriginalPaper

Depsipeptide (FR901228, NSC-630176) pharmacokinetics in the rat by LC/MS/MS

OriginalPaper

Phase II trial of topotecan in advanced gastric cancer: A Southwest Oncology Group study

OriginalPaper

A phase II Southwest Oncology Group study of cisplatin and continuous infusion vinblastine in the treatment of advanced soft tissue sarcoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits